Portopulmonary hypertension in the current era of pulmonary hypertension management
- 4 March 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 73 (1), 130-139
- https://doi.org/10.1016/j.jhep.2020.02.021
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Epoprostenol-Induced Hypersplenism in Portopulmonary HypertensionThe American Journal of the Medical Sciences, 2012
- Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertensionEuropean Respiratory Journal, 2012
- Portopulmonary HypertensionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Portopulmonary HypertensionSeminars in Respiratory and Critical Care Medicine, 2012
- Haemodynamic and renal effects of tadalafil in patients with cirrhosisWorld Journal of Gastroenterology, 2010
- Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment SubgroupsAmerican Journal of Transplantation, 2008
- Portopulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertensionThe Esophagus, 2006
- Pulmonary Hemodynamics and Perioperative Cardiopulmonary-Related Mortality in Patients With Portopulmonary Hypertension Undergoing Liver TransplantationLiver Transplantation, 2000